Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Journal of Cardiac Failure
|
December 20, 2005
Rationale and design of the enoximone clinical trials program
Brian D Lowes, Simon F Shakar, Marco Metra, et al.
Clinical Trials (London, England)
|
February 1, 2017
Rejoinder
Thomas R Fleming, David L DeMets, Matthew T Roe, et al.
American Heart Journal
|
June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial
Orly Vardeny, Jacob A Udell, Jacob Joseph, et al.
Clinical Trials (London, England)
|
April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challenges
Thomas R Fleming, David L DeMets, Matthew T Roe, et al.
Circulation
|
November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
Journal of the American College of Cardiology
|
April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
European Journal of Heart Failure
|
June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF
Pooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Circulation
|
November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
European Heart Journal
|
March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
The Lancet. Diabetes & Endocrinology
|
December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
Peter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Journal of Cardiac Failure
|
December 20, 2005
Rationale and design of the enoximone clinical trials program
Brian D Lowes, Simon F Shakar, Marco Metra, et al.
Clinical Trials (London, England)
|
February 1, 2017
Rejoinder
Thomas R Fleming, David L DeMets, Matthew T Roe, et al.
American Heart Journal
|
June 18, 2018
High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial
Orly Vardeny, Jacob A Udell, Jacob Joseph, et al.
Clinical Trials (London, England)
|
April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challenges
Thomas R Fleming, David L DeMets, Matthew T Roe, et al.
Circulation
|
November 19, 2019
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
Felipe A Martinez, Matteo Serenelli, Jose C Nicolau, et al.
Journal of the American College of Cardiology
|
April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
European Journal of Heart Failure
|
June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF
Pooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Circulation
|
November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
European Heart Journal
|
March 30, 2020
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Kieran F Docherty, Pardeep S Jhund, Silvio E Inzucchi, et al.
The Lancet. Diabetes & Endocrinology
|
December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
Peter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Page
of 10